Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
Madeleine R HeldmanKerstin L EdlefsenGregory PepperSiddhartha G KapnadakRobert M RakitaCynthia E FisherAjit P LimayePublished in: Transplant infectious disease : an official journal of the Transplantation Society (2022)
Risk of PTLD among SOTRs with discordant VCA and EBNA-1 may be intermediate between those with concordantly positive and negative serology. If confirmed in future studies, revision of national EBV serology reporting to include both VCA and EBNA results may be needed to optimize PTLD risk stratification.